NOXXON begins clinical testing of ground-breaking blood cancer treatment
Berlin – German NOXXON Pharma AG has kicked off clinical testing of a completely new compound that helps to mobilise haematopoietic stem cells (HSC) from the bone marrow of blood cancer patients undergoing autologous stem cell transplantation. The mirror-image oligonucleotide (L-Aptamer, Spiegelmer) NOX-A12 binds and neutralises the chemokine stromal cell-derived factor-1 (SDF-1, CXCL12), which regulates the homing and retention of HSCs in the bone marrow. NOXXON has said that it will be seeking approval of the compound, which is now being tested in up to 42 volunteers up to 2014. The results obtained in the phase I study will form the basis for a phase II program to be conducted by mid-2010 in patients with Multiple Myeloma or non-Hodgkin’s Lymphoma. NOX-A12 is NOXXON’s second drug candidate to enter a clinical stage of development within only five months.